Please use this identifier to cite or link to this item:
Title: Early experience and quality of life in SBRT prostate cancer boost of 9 Gy in a phase II trial
Author: Ferrer, Ferran
Pont, Àngels
Blas, Rodolfo de
Boladeras, Anna
Garin, O.
Ventura, Montse
Zardoya, Eva
Delgado, J.
Condom, E.
Merino, E.
Mases, Joel
Castells-Esteve, Manel
Guix, Inés
Suarez, Jose Francisco
Gonzalez, Javier
Almendros, Sonia
Garcia, M.
Berenguer, Miguel Ángel
Garcia, N.
Stefanovic, M.
Gutierrez, Cristina
Picon, Cristina
Ferrer, Montserrat
Guedea Edo, Ferran
Keywords: Radioteràpia
Càncer de pròstata
Prostate cancer
Issue Date: 1-Apr-2019
Publisher: Elsevier BV
Abstract: Purpose or ObjectiveExtracranial stereotactic body radiation therapy (SBRT) allows delivering high doses per fraction with high accuracy to the prostatic gland in a low number of fractions.Dose escalation in normofractionaded radiation prostate cancer trials showed an increased toxicity.In order to evaluate the feasibility and toxicity of a regimen of a single dose hypofractionated prostate stereotactic boost a phase II study was undertaken. Self-reported quality of life (QOL) measures were also obtained in order to better define the possible deleterious effect of treatment.
Note: Reproducció del document publicat a:
It is part of: Radiotherapy and Oncology, 2019, vol. 133, p. S830-S831
Related resource:
ISSN: 0167-8140
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS0167814019319590.pdf2.28 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons